Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease by Kis E et al.
 Kidney Blood Press Res 2018;43:134-142
DOI: 10.1159/000487367
Published online: February 14, 2018
© 2018 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 134
Kis et al.: Cardiac MRI of the Myocardium in CKD
Review
Accepted: February 4, 2018
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution 
for commercial purposes as well as any distribution of modified material requires written permission.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
www.karger.com/kbr
Cardiac Magnetic Resonance Imaging of 
the Myocardium in Chronic Kidney Disease
Eva Kisa    Laszlo Ablonczya    György S. Reuszb
aGottsegen György Hungarian Institute of Cardiology, Budapest, b1st Department of Pediatrics, 
Semmelweis University, Budapest, Hungary
Key Words
Chronic kidney disease • Cardiovascular disease • Myocardial fibrosis • Cardiac magnetic 
resonance imaging
Abstract
Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious 
effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV 
damage is of crucial importance in preventing major CV events. Myocardial fibrosis is one of 
the major consequences of progressive CKD, as it may lead to reentry arrhythmias and long-
term myocardial dysfunction predisposing to sudden death and/or congestive heart failure. 
Subclinical myocardial fibrosis, with a potential key role in the development of uraemic cardiac 
disease, can be measured and characterised by appropriate cardiac magnetic resonance (CMR) 
techniques. Fibrosis detection was initially based on the contrast agent gadolinium, due to 
the superiority in sensitivity and accuracy of contrast-based methods in fibrosis assessment 
relative to native techniques. However, the severe consequences of gadolinium administration 
in uraemia (nephrogenic systemic fibrosis) have forced practitioners to re-evaluate the 
methodology. In the present overview, we review the possible contrast-based and contrast 
agent-free CMR techniques, including native T1 relaxation time, extracellular volume and 
global longitudinal strain measurement. The review also summarises their potential clinical 
relevance in CKD patients based on recently published studies.
Cardiovascular disorder in chronic kidney diseaseChronic kidney disease (CKD) is a common cardiovascular (CV) risk factor. Early stages of CKD are often underdiagnosed, whereas their deleterious effects on the cardiovascular system are already at work. According to the large meta-analysis by the Chronic Kidney Disease Prognosis Consortium, the slow, gradual increase in cardiovascular risk is already 
present in CKD patients at 60-75 ml/min/1.73m² glomerular filtration rates [1], with CKD 
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rightly deserving its designation as a silent killer. Thus, assessment of the early cardiovascular damage and risk conferred by CKD in its early stages is of crucial importance with regard to prevention of major cardiovascular events.The cause of cardiovascular disease in CKD is multifactorial. Conventional and non-conventional risk factors both contribute to the increase in CV morbidity and mortality (Table 1).With the progression of CKD, risk factors resulting from decreased kidney function gradually gain importance over the traditional risk factors. This prominence has been elegantly 
shown by the relative efficacy of lipid lowering therapy in CKD patients [4, 5] suggesting a different causality in cardiovascular diseases in the CKD and non-CKD population.
Endocrine abnormalities – such as increased  parathyroid hormone and  fibroblast growth factor 23 levels, dysregulation of calcium and phosphate homeostasis along with 
poor vitamin K status [6],  concomitant vascular calcification, increased arterial stiffness 
[7-9], anaemia as well as hemodynamic fluctuations – may contribute to the progression 
of cardiovascular disease, left and right ventricular [10], cardiac disease, left ventricular 
hypertrophy (LVH) and myocardial fibrosis [2, 3, 11, 12].Cardiac magnetic resonance (CMR) is a useful imaging tool not only to characterise ventricular volumes but also to assess the properties and consequential pathology of 
myocardial tissue. Using tissue characterisation properties, Mark et al. identified non-
ischemic, uraemia-specific LVH in 72% of dialysed patients [13].However, although increased left ventricular mass is often recognised as a surrogate 
endpoint of all-cause mortality [14, 15], a recent meta-analysis by Badve et al. [16] involving 6732 CKD patients concluded that there was no clear evidence of an association between the change in left ventricular mass and mortality. Thus there is an urgent need for complementary 
markers of myocardial function and damage in all patients alters [17].
Detecting myocardial fibrosis with cardiac magnetic resonance in chronic kidney 
disease
Myocardial fibrosis is a hallmark consequence of progressive CKD. Uraemic myocardial 
fibrosis may cause reentry arrhythmias and long-term myocardial dysfunction predisposing to sudden death and/or congestive heart failure in end-stage renal disease. Accordingly, 
Charytan et al. [18] observed a 12% increase in myocardial fibrosis in stage 3-4 CKD patients 
and a 77% increase in stage 5 CKD comparatively to patients with preserved renal function. 
Table 1. Traditional and CKD-related cardiovascular risk factors [2,3]
1 
   Traditional CV risk factors CKD-related (non-traditional) risk factors Older age Type (diagnosis) of CKD Male gender Decreased GFR White race Proteinuria (albuminuria) Hypertension Renin-angiotensin system activity Higher LDL cholesterol Extracellular fluid volume overload Lower HDL cholesterol Electrolyte imbalance Diabetes mellitus Dysregulation of calcium and phosphate homeostasis Smoking Dyslipidaemia Physical inactivity Anaemia Menopause Malnutrition Psychosocial stress Inflammation Family history of CV disease Infection  Thrombogenic factors  Oxidative stress  Homocysteine  Uremic toxins  
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Current treatment modalities for CKD do not adequately correct for fibrosis, apoptosis and capillary degeneration. Earlier detection of myocardial changes should therefore allow elaborating new strategies for a more effective intervention.
Subclinical myocardial fibrosis with a potential key role in the progression of uraemic cardiac disease can be measured and characterised by appropriate cardiac CMR techniques.Late gadolinium enhancement (LGE) was heralded as a promising tool for the detection 
of myocardial fibrosis. LGE is based on the delayed contrast agent wash-in and wash-out in tissues with increased extracellular space. LGE was originally developed to detect chronic 
infarcted myocardium, such as fibrous scar tissue, but has also been found useful in the 
diagnosis of cardiomyopathies. Accordingly, while LGE was observed in only 6% of cases in early CKD patients (stage 2-3) with no clinical evidence of cardiovascular disease, in the 
aforementioned Charytan et al. study with 72% LVH incidence in the stage 5 CKD group, 
the occurrence of LGE was found as high as 28%. The authors described the pathological LGE type as less intense than the infarction pattern without subendocardial dominance. The importance of the new uraemic pattern of LGE is that it may help differentiate CKD-related 
diffuse fibrosis from ischemic scarring in the CKD population. Diffuse fibrosis identified by LGE has been associated with increased LV mass suggesting that left ventricular hypertrophy 
in stage 5 CKD patients is pathological [13].
However, LGE is not sufficiently sensitive to detect the diffuse form of myocardial fibrosis since the technique relies on relative differences in signal intensities, notably considering 
the lowest myocardial signal intensity as normal (regardless of the degree of fibrosis). 
Further investigations and developments were planned in the field of contrast (gadolinium) 
- enhanced fibrosis detection.
Nephrogenic Systemic Fibrosis in CKD patientsIn 2006, the safety of gadolinium-enhanced magnetic resonance imaging became questionable in CKD patients based on observations of fatal cases of Nephrogenic Systemic 
Fibrosis (NSF) with a possible causal relationship to gadolinium use [19-21].NSF typically begins on the skin and may involve underlying joints. This loss of skin 
flexibility and joint contractures can result in permanent pain and decreased mobility. A 
rapid progression has been observed in 5% of NSF patients, with internal organs such as 
lung, heart, liver and kidney also potentially affected [22].The use of the highly toxic gadolinium as contrast agent is made possible by its embedding into chelates. Given that the chelates are excreted by the kidney, the duration of 
chelate exposure is hence related to renal function. In CKD patients, chelates have sufficient 
time to release into the extracellular fluid. However, there is a difference between linear 
and macrocyclic gadolinium chelates with regard to their gadolinium binding affinity. The linear gadolinium-based agents dissociate more easily, thus releasing gadolinium more 
rapidly. They are consequently more toxic, resulting in a more potent fibroblast stimulation 
than the more stable macrocyclic agents [23]. Based on these properties, current guidelines distinguish between high, medium and low risk agents. According to the European Medicines Agency guideline, the use of high risk gadolinium agents in patients with severe renal 
impairment (eGFR ≤30 ml/min/1.73m²) is contraindicated and there are strong warnings regarding the use of medium and low NSF risk gadolinium agents in patients with severe 
renal impairment. Given the absence of specific and effective treatment, therapeutic activity is limited to palliation and prevention.In recent years, due to the mandatory assessment of renal function prior to MRI and caution in patients with severe renal impairment, the number of reported NSF cases has drastically decreased.
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Assessment of uraemic myocardial disease after the NSF eraGiven the limitations of contrast-based myocardial CMR in CKD patients, the development of new diagnostic strategies was initiated along two directions. The first was 
to detect early myocardial CMR changes in predialytic patients (eGFR ≥15 ml/min/1.73m²) using gadolinium-based contrast agents. The second approach focused on the development of new native (contrast-free) CMR methodologies in CKD patients with moderate to severe 
renal impairment (eGFR ≤60 ml/min/1.73m²).
In the following subsections, we will first review certain CMR techniques that may 
potentially detect myocardial fibrosis or dysfunction in non-CKD patients. The common goal of these techniques is to identify the high-risk patients who were undetected by traditional 
LGE assessment. Secondly, we will briefly review the most recent results obtained by the use of these techniques.
Elevated native T1 relaxation time (T1). Myocardial interstitial volume expansion (diffuse 
or focal fibrosis, cardiomyopathy or amyloid) and oedema may represent the pathological background of elevated native T1. In order to obtain consistent and comparable results, 
native T1 measurements should be performed at the same field strength, cardiac phase and 
cardiac region [24]. Although native T1 is highly dependent on technical parameters, there are studies supporting its clinical relevance (including predictive value or correlation with 
histological fibrosis). Native myocardial T1 is correlated with serum cardiac biomarkers 
of disease severity in amyloidosis and is predictive of mortality in this patient group [25]. Native T1 values are also increased in patients with aortic stenosis. In this patient group, the length of T1 values is correlated with the increase in left ventricular mass index (LVMi) as 
well as with the degree of biopsy-quantified fibrosis [26].
Extracellular volume (ECV) assessment. ECV is a T1-derived histologically validated CMR parameter. Estimation of ECV requires the measurement of myocardial and blood T1 before and after administration of contrast agents. ECV values may be more reproducible between 
different field strengths and acquisition techniques than both native and post-contrast T1 
[27, 28].Although there is a strong correlation between ECV and the histological extent of 
myocardial fibrosis [27], its main disadvantage lies in that ECV measurement is based on the use of contrast agent. ECV can nonetheless be useful in several patient groups, for example for differentiating hypertrophic cardiomyopathy (HCM) from athlete’s heart. In athlete’s heart, hypertrophy is associated with a reduction in ECV, as opposed to an increase in ECV in HCM patients. ECV may also be of prognostic value in selected populations. In a large diabetic study, ECV was associated with mortality and/or incident hospitalisation for heart 
failure [29].
Use of dynamic parameters to describe myocardial properties. In addition to T1 and its derivatives, dynamic parameters can also be used to describe myocardial status. Strain imaging can quantify myocardial mechanics such as shortening and torsion. CMR is usually considered the reference standard for myocardial strain, although echocardiography is more readily available in the clinical setting and shows reasonable agreement with CMR.Global longitudinal strain (GLS) represents the most accurate strain parameter for 
identifying subclinical myocardial dysfunction in echocardiography studies [30]. Although 
impaired GLS is associated with an increased risk of mortality in stage 4-5 CKD patients, 
there is no clear evidence to date confirming the early predictive value of GLS in patients with ≥60 ml/min/1.73m² [31, 32].
Assessment of myocardium using gadolinium-based contrast agent (GBCA) in CKD patients
After a long quiet period, Edwards et al. in 2015 presented the first study assessing 
diffuse interstitial fibrosis using T1-mapping in 43 stage 2-4 CKD patients with no history or 
symptoms of cardiovascular disease or diabetes [33]. In addition to routine assessment and 
native T1 evaluation, the authors assessed ECV using low dose macrocyclic GBCA.
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The CKD group displayed an increased ECV compared to controls as well as hypertensive 
subjects with normal kidney function (CKD: 0.28; hypertensive: 0.25; control: 0.25, 
respectively; p <0.05). The ECV frequency histogram for CKD patients was shifted rightward with a higher mean septal ECV. Such elevation of ECV in early CKD, but not in hypertensive 
patients, suggests that the development of diffuse interstitial fibrosis is not dependent on increased blood pressure.
Furthermore, both ECV and native T1, considered as parameters of diffuse fibrosis in the above study, have also shown an association with global longitudinal systolic strain (GLS), a more sensitive predictor of both overall and CV mortality than the routinely-used ejection 
fraction in patients with CKD stage 4-5 [34].
Assessment of the myocardium without contrast agent in CKD patients
As stated earlier, myocardial fibrosis detection was initially based on the contrast agent 
gadolinium. The sensitivity and accuracy of these methods in fibrosis assessment is superior to native techniques. However, the severe consequences of gadolinium administration forced a return to the primarily-used native T1 time measurement. This resulted in a long period 
in which no studies on contrast-free myocardial fibrosis detection in CKD patients were available, possibly due in part to methodological uncertainties.
In 2016, Graham-Brown et al. and Rutherford et al. [35, 36] published promising results in dialysis populations using native T1 as a novel CMR technique. Not only were the studies conducted in parallel, but both groups also used the same methodology. The assessments were perfomred on a 3-Tesla magnet using a modified look-locker inversion recovery 
sequence (which was manufacturer-specific). This similarity hence enabled the comparison 
of these two studies without serious T1-specific limitations.
In the Graham-Brown et al. study, native T1 and strain parameters were measured on a global and segmental level in 35 haemodialysis patients. The authors found elevated native 
global T1 times and septal-nonseptal differences (septal T1 1293 vs. non-septal T1 1252 ms respectively). Elevated global T1 levels were correlated with global strain parameters while 
septal native T1 was correlated with septal systolic strain. Graham-Brown et al. not only presented the possibility of non-invasive T1 mapping in a haemodialysis population, but also suggested that the interventricular septum is the most sensitive region with regard to the 
development of myocardial fibrosis [35].
Rutherford et al. [36] found that global, septal and midseptal native T1 values were 
significantly higher in haemodialysis patients compared to healthy volunteers (global 1171 
vs. 1154 ms; septal 1184 vs. 1163 ms; midseptal 1184 vs. 1161 ms respectively) and that native T1 was correlated with left ventricular mass indices. Although these authors found 
no differences in native T1 at the segmental level (in contrast to Graham-Brown et al. [35]), a correlation was observed between septal native T1 and clinical parameters (troponin level 
and corrected QT interval). An important finding of the study featured the demonstration 
of a significant correlation between native T1 and LVMi (global T1: R=0.452, p= 0.008, 
septal T1 R=0.449, p= 0.009, midseptal T1 R=0.498 p= 0.003 respectively). Moreover, global 
longitudinal strain was significantly reduced and correlated with LVMi (R= 0.426), along 
with a trend toward a correlation of GLS with galectin-3 (R=0.344, p=0.05) a biomarker of 
cardiac fibrosis.As previously mentioned, one of the most important determinants of native T1 is oedema. Although native T1 times are elevated in dialysis patients, the reproducibility 
of native T1 has not been investigated in this population group with highly variable fluid 
status. Most recently, Graham-Brown et al. [37] published a study on the reproducibility of T1 mapping in haemodialysis patients in which they found excellent inter-study, inter-observer and intra-observer variability of native T1. In dialysed patients, changes in body 
weight between the examinations (reflecting the fluid status of the patients) was correlated 
with changes in LV end-diastolic volume (LVEDV) (r = 0.682; P = 0.03). However, based on 
linear regression analysis, T1 change was unaffected by LVEDV or weight fluctuation. The 
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authors concluded that myocardial native T1 is reproducible in haemodialysis patients and 
unaffected by alterations in fluid status.In contrast, a recent study on native T1 measurement in CKD patients published by Wang 
et al. [38] failed to show significant differences in native T1 in patients with end-stage renal disease compared to controls. The higher control native T1 levels compared to the other 
above 3-Tesla studies (Wang et al.: 1253.1 ± 71.6 ms, Graham-Brown et al.: 1085.2 (1066–
1109.2) ms, Rutherford et al.: 1154 ± 32 ms) highlight not only the difficulties associated with native T1 measurements, but also raise the question of the comparability of native T1 in different studies. Wang et al. also reported on the value of native T1-rho sequences in CKD patients. The “rho” in the sequence name refers to a “ro”tating frame with the sequence having elements of both T1 and T2 weighting. They found significantly higher values in 
dialysed patients compared to controls (52.2 ± 4.0 ms vs. 49.4 ± 2.6 ms, P = 0.001). The 
authors concluded that T1-rho might be associated with myocardial fibrosis and may better 
characterise myocardial injury than T1 and T2. However, the significance and predictive 
value of T1 rho measurement in CKD patients still remain to be clarified.
Conclusion
Recent CMR studies have identified markers of subclinical left ventricular disease in 
chronic kidney disease. While these studies do not confirm the establishment of a particular and singular powerful tool for myocardial assessment, the combination of these safe imaging techniques (native T1 time, T1-rho, longitudinal strain, LVMi) and biomarkers (troponin, brain natriuretic peptide, galectin-3) should help practitioners perform highly predictive risk assessment in CKD patients.
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